

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ngai Shun Holdings Limited**  
**毅信控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 01246)**

**APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board is pleased to announce that Dr. Wong Yun Kuen has been appointed as the executive Director of the Company with effect from 5 July 2016.

**APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Ngai Shun Holdings Limited (the “**Company**”) is pleased to announce that Dr. Wong Yun Kuen (“**Dr. Wong**”) has been appointed as the executive Director of the Company with effect from 5 July 2016. The biographical details of Dr. Wong are set out as follows:

Dr. Wong, aged 58, received a Ph.D. Degree from Harvard University, and was a “Distinguished Visiting Scholar” at Wharton School of the University of Pennsylvania. He has worked in financial industries in the United States and Hong Kong for many years, and has considerable experience in corporate finance, investment and derivative products.

Dr. Wong is a member of Hong Kong Securities and Investment Institute. He is an Adjunct Professor of Syracuse University, USA, the chairman and an executive director of UBA Investments Limited (Stock Code: 768), and an independent non-executive director of Bauhaus International (Holdings) Limited (Stock Code: 483), China Sandi Holdings Limited (Stock Code: 910), DeTai New Energy Group Limited (Stock Code: 559), Far East Holdings International Limited (Stock Code: 36), GT Group Holdings Limited (Stock Code: 263), Kaisun Energy Group Limited (Stock Code: 8203), Kingston Financial Group Limited (Stock Code: 1031) and Sincere Watch (Hong Kong) Limited (Stock Code: 444).

Dr. Wong was also an independent non-executive director of KuangChi Science Limited (Stock Code: 439) (June 2007 to August 2014), Huge China Holdings Limited (Stock Code: 428) (September 2004 to January 2015), Kong Sun Holdings Limited (Stock Code: 295) (April 2007 to November 2014) and Huajun Holdings Limited (Stock Code: 377) (October 2010 to September 2014). All the companies mentioned above are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

There is no service contract between the Company and Dr. Wong and Dr. Wong is appointed for an initial term of one year commencing from 5 July 2016, which is automatically renewable for successive terms of one year upon expiry of the then current term. He will hold office until the next general meeting of the Company and will retire at that general meeting but will be eligible for re-election pursuant to the memorandum and articles of association of the Company. The remuneration of Dr. Wong will be determined by the remuneration committee of the Company and the Board by reference to his duties and responsibilities with the Company, the remuneration policy of the Company as well as prevailing market rates.

Save as disclosed above, Dr. Wong does not hold any position in the Company or any of its subsidiaries, or have any other major appointments and professional qualifications. He does not have any relationship with any Directors, senior management or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company.

Moreover, as at the date of this announcement, Dr. Wong does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (as defined under Part XV of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong)) of the Company.

Save as disclosed above, Dr. Wong did not hold any other directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the three years prior to the date of this announcement.

Save as disclosed above, there are no other matters concerning Dr. Wong that need to be brought to the attention of the shareholders of the Company nor is there any information relating to Dr. Wong that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

The Board would like to extend its warmest welcome to Dr. Wong for joining the Board.

By order of the Board  
**Ngai Shun Holdings Limited**  
**Mock Wai Yin**  
*Executive Director and Chairman*

Hong Kong, 5 July 2016

*As at the date of this announcement, the Company has (i) three executive Directors, namely Mr. Mock Wai Yin, Mr. Wang Xin and Dr. Wong Yun Kuen; (ii) one non-executive Director, namely Mr. Chui Kwong Kau and (iii) three independent non-executive Directors, namely Mr. Lam Chi Wai, Ms. Lau Mei Ying and Ms. Thadani Jyoti Ramesh.*

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*